Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 394

1.

Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.

Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, André J, Dumaz N, Ortonne N.

Hum Pathol. 2013 Sep;44(9):1902-11. doi: 10.1016/j.humpath.2013.01.025. Epub 2013 May 9.

2.

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.

Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J.

Br J Cancer. 2013 Aug 6;109(3):559-64. doi: 10.1038/bjc.2013.373. Epub 2013 Jul 16.

3.

[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Lázár V.

Magy Onkol. 2013 Jun;57(2):96-9. doi: MagyOnkol.2013.57.2.96. Epub 2013 May 20. Hungarian.

4.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.

PMID:
15948115
5.

Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases.

Turri-Zanoni M, Medicina D, Lombardi D, Ungari M, Balzarini P, Rossini C, Pellegrini W, Battaglia P, Capella C, Castelnuovo P, Palmedo G, Facchetti F, Kutzner H, Nicolai P, Vermi W.

Head Neck. 2013 Aug;35(8):1066-77. doi: 10.1002/hed.23079. Epub 2012 Jul 12.

PMID:
22791410
6.

NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.

van Engen-van Grunsven AC, Küsters-Vandevelde HV, De Hullu J, van Duijn LM, Rijntjes J, Bovée JV, Groenen PJ, Blokx WA.

Gynecol Oncol. 2014 Jul;134(1):10-4. doi: 10.1016/j.ygyno.2014.04.056. Epub 2014 May 5.

PMID:
24802725
7.

KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.

Zebary A, Omholt K, Vassilaki I, Höiom V, Lindén D, Viberg L, Kanter-Lewensohn L, Johansson CH, Hansson J.

J Dermatol Sci. 2013 Dec;72(3):284-9. doi: 10.1016/j.jdermsci.2013.07.013. Epub 2013 Aug 8.

PMID:
23993026
8.

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.

Lázár V, Ecsedi S, Szöllosi AG, Tóth R, Vízkeleti L, Rákosy Z, Bégány A, Adány R, Balázs M.

Mod Pathol. 2009 Oct;22(10):1367-78. doi: 10.1038/modpathol.2009.109. Epub 2009 Jul 24.

9.

Comparison of molecular abnormalities in vulvar and vaginal melanomas.

Aulmann S, Sinn HP, Penzel R, Gilks CB, Schott S, Hassel JC, Schmidt D, Kommoss F, Schirmacher P, Kommoss S.

Mod Pathol. 2014 Oct;27(10):1386-93. doi: 10.1038/modpathol.2013.211. Epub 2014 Mar 7.

10.

[ Spectrum of oncogene mutations is different in melanoma subtypes].

Mazurenko NN, Tsyganova IV, Lushnikova AA, Ponkratova DA, Anurova OA, Cheremushkin EA, Mikhailova IN, Demidov LV.

Mol Biol (Mosk). 2015 Nov-Dec;49(6):1022-9. doi: 10.7868/S0026898415060166. Russian.

PMID:
26710785
11.

Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.

Tseng D, Kim J, Warrick A, Nelson D, Pukay M, Beadling C, Heinrich M, Selim MA, Corless CL, Nelson K.

J Am Acad Dermatol. 2014 Aug;71(2):229-36. doi: 10.1016/j.jaad.2014.03.033. Epub 2014 May 17.

12.

Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.

Yaman B, Akalin T, Kandiloğlu G.

Am J Dermatopathol. 2015 May;37(5):389-97. doi: 10.1097/DAD.0000000000000241.

PMID:
25357015
13.

The role of CCND1 alterations during the progression of cutaneous malignant melanoma.

Vízkeleti L, Ecsedi S, Rákosy Z, Orosz A, Lázár V, Emri G, Koroknai V, Kiss T, Ádány R, Balázs M.

Tumour Biol. 2012 Dec;33(6):2189-99. doi: 10.1007/s13277-012-0480-6. Epub 2012 Sep 23.

PMID:
23001925
14.

BRAF and c-kit gene copy number in mutation-positive malignant melanoma.

Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ.

Hum Pathol. 2006 May;37(5):520-7.

PMID:
16647948
15.

KIT amplification and gene mutations in acral/mucosal melanoma in Korea.

Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH, Kim KM.

APMIS. 2011 Jun;119(6):330-5. doi: 10.1111/j.1600-0463.2011.02737.x. Epub 2011 Mar 24.

PMID:
21569090
16.

Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases.

Langer R, Becker K, Feith M, Friess H, Höfler H, Keller G.

Mod Pathol. 2011 Apr;24(4):495-501. doi: 10.1038/modpathol.2010.220. Epub 2010 Dec 3.

17.

Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.

Pracht M, Mogha A, Lespagnol A, Fautrel A, Mouchet N, Le Gall F, Paumier V, Lefeuvre-Plesse C, Rioux-Leclerc N, Mosser J, Oger E, Adamski H, Galibert MD, Lesimple T.

J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1530-8. doi: 10.1111/jdv.12910. Epub 2015 Jan 26.

PMID:
25623140
18.

Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.

Gos A, Jurkowska M, van Akkooi A, Robert C, Kosela-Paterczyk H, Koljenović S, Kamsukom N, Michej W, Jeziorski A, Pluta P, Verhoef C, Siedlecki JA, Eggermont AM, Rutkowski P.

Ann Surg Oncol. 2014 Dec;21(13):4317-23. doi: 10.1245/s10434-014-3799-y. Epub 2014 May 28.

19.

NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

Tschandl P, Berghoff AS, Preusser M, Burgstaller-Muehlbacher S, Pehamberger H, Okamoto I, Kittler H.

PLoS One. 2013 Jul 8;8(7):e69639. doi: 10.1371/journal.pone.0069639. Print 2013.

20.

BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.

Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB.

J Cutan Pathol. 2012 Sep;39(9):821-5. doi: 10.1111/j.1600-0560.2012.01950.x. Epub 2012 Jul 19.

Items per page

Supplemental Content

Write to the Help Desk